Wells Fargo
NVCT icon

Wells Fargo’s Nuvectis Pharma NVCT Stock Holding History

Wells Fargo’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$287K Buy
15,594
+9,975
+178% +$112K ﹤0.01% 4970
2026
Q1 		$43.4K Sell
5,619
-11,310
-67% -$96.9K ﹤0.01% 5499
2025
Q4 		$128K Buy
16,929
+9,022
+114% +$58.8K ﹤0.01% 5284
2025
Q3 		$47.6K Buy
7,907
+1,254
+19% +$8.62K ﹤0.01% 5566
2025
Q2 		$49.7K Buy
+6,653
New +$60.3K ﹤0.01% 5506
2024
Q2 		– Sell
-2,200
Closed -$18K – 7291
2024
Q1 		$18K Buy
2,200
+298
+16% +$2.53K ﹤0.01% 5604
2023
Q4 		$15.9K Buy
1,902
+437
+30% +$3.9K ﹤0.01% 5717
2023
Q3 		$18.9K Sell
1,465
-1,380
-49% -$20K ﹤0.01% 5623
2023
Q2 		$45.4K Buy
2,845
+2,820
+11,280% +$45K ﹤0.01% 5459
2023
Q1 		$328 Hold
25
– – ﹤0.01% 6640
2022
Q4 		$188 Buy
25
+1
+4% +$7 ﹤0.01% 6634
2022
Q3 		$0 Buy
24
+3
+14% +$28 ﹤0.01% 7145
2022
Q2 		$0 Buy
21
+1
+5% +$12 ﹤0.01% 7277
2022
Q1 		$0 Buy
+20
New +$139 ﹤0.01% 7584

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Wells Fargo's NVCT Position: Q2 2026 in Review

Wells Fargo increased its Nuvectis Pharma (NVCT) stake by 178% in Q2 2026, buying an estimated $112K and bringing the position to 15,594 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #4970.

Wells Fargo first reported a position in NVCT in Q1 2022 and has held it in 14 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Wells Fargo held 15,594 shares of Nuvectis Pharma worth $287K as of Q2 2026.
  • Wells Fargo bought 9,975 Nuvectis Pharma shares in Q2 2026, an estimated $112K.
  • Nuvectis Pharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4970 holding.
  • Wells Fargo first reported a position in Nuvectis Pharma in Q1 2022 and has held it in 14 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.